Ind-Swift Laboratories Limited
All news and filings related to Ind-Swift Laboratories Limited.
View all news & filings- Medium impact
Ind-Swift Laboratories Allots 70 Lakh Warrants to Promoter Group Entity
Ind-Swift Laboratories Limited allotted 70,00,000 warrants to Essix Biosciences Limited, a promoter group entity. The issue price is ₹196 per warrant, with ₹49 received upfront, totaling ₹34.30 crore.
Read the summary - Low impact
Ind-Swift Laboratories Publishes AGM Notice and E-Voting Details
Ind-Swift Laboratories published the notice for its 31st Annual General Meeting and e-voting details on September 6, 2026. The Annual Report for FY26 is also available on the company's website and stock exchanges.
Read the summary - Medium impact
Ind-Swift Laboratories Announces 31st AGM on Sep 30, 2026, to Discuss FY26 Financials and Director Appointments
Ind-Swift Laboratories will hold its 31st AGM on September 30, 2026, via VC/OAVM. The meeting will approve the FY26 audited financial statements and consider the re-appointment of Sh. Navrattan Munjal. Sh. Amit Mathur's appointment as an Independent Director for five years (Sept 2026-Sept 2031) will also be voted on. Remote e-voting is available from Sep 27-29, 2026.
Read the summary - Medium impact
Ind-Swift Labs Sets Preferential Issue Price at ₹196 Per Warrant
Ind-Swift Laboratories Limited's Preferential Issue Committee set the issue price for warrants at ₹196. This price is determined based on SEBI ICDR Regulations, with the 10-day VWAP being ₹195.98. A valuation report suggested ₹189.46. The relevant date for floor price determination was July 6, 2026.
Read the summary - Medium impact
Ind-Swift Laboratories Appoints Amit Mathur as Additional Director, Schedules 31st AGM for Sep 30
Ind-Swift Laboratories appointed Amit Mathur as an Additional Non-Executive Independent Director. The company will hold its 31st AGM on September 30, 2026, via VC/OAVM. The Register of Members will close from September 24-30, 2026. Care Ratings appointed as Monitoring Agency for preferential issue.
Read the summary - Low impact
Ind-Swift Laboratories Limited Clarifies Share Volume Spurt, Cites Market Driven Factors
Ind-Swift Laboratories Limited is clarifying a recent spurt in its share volume and price. The company informed the NSE that it is unaware of any specific reason for the surge, attributing it to market-driven factors. Management stated they are not responsible for the movement and reaffirmed compliance with SEBI regulations.
Read the summary - Low impact
Ind-Swift Laboratories Limited Clarifies Share Volume Spurt, Cites Market Driven Factors
Ind-Swift Laboratories Limited clarified a recent spurt in its share volume, stating it is unaware of any specific reason and attributes it to market-driven factors. The company confirmed adherence to SEBI regulations and consistent disclosure of material information.
Read the summary - High impact
Ind-Swift Laboratories Q1 FY27: Revenue Up 21%, EBITDA Margin Expands to 17.91%
Ind-Swift Laboratories reported Q1 FY27 revenue of ₹186.08 crore, up 21.16% YoY. EBITDA margin expanded to 17.91% from 5.33%. CDMO partnerships are expected to contribute ₹200-220 crore in FY27. The company plans ₹250 crore capex over 2.5 years and targets ₹1500 crore revenue by FY30.
Read the summary - Medium impact
Ind-Swift Labs to Invest ₹45 Cr to Upgrade Jammu Facility for EUGMP/PICS Compliance
Ind-Swift Laboratories will invest ₹45 crores to upgrade its Jammu facility for EU-GMP/PICS compliance, targeting ₹100 crores in additional revenue from regulated markets by FY 2029-30. The facility is expected to be approved by early 2028. For Q1 FY27, the company reported a 21.16% YoY increase in operating income to ₹186.08 crore and PAT growth to ₹24.68 crore.
Read the summary - Low impact
Ind-Swift Laboratories Releases Audio Recording of Q1 FY27 Earnings Conference Call
Ind-Swift Laboratories Limited released the audio recording of its Q1 FY27 earnings conference call held on August 17, 2026. The call discussed financial results for the quarter ended June 30, 2026. The transcript will be uploaded shortly.
Read the summary - High impact
Ind-Swift Labs Q1FY27: EBITDA Up 2.85x to ₹33.32 Cr, Revenue Grows 21.16% YoY
Ind-Swift Laboratories reported a strong Q1FY27 with operational EBITDA up 2.85x YoY to ₹33.32 crore and margins at 17.91%. Standalone revenue grew 21.16% YoY to ₹186.08 crore, with PAT (excl. exceptional items) up 2.04x YoY to ₹24.68 crore. CDMO partnerships and own-brands with Viatris, Manx, and Arrotex are expected to add ₹200-220 crore revenue in FY27. The company projects over 50% revenue growth in FY27.
Read the summary - Low impact
Ind-Swift Laboratories Ltd. Schedules Q1 FY27 Earnings Call for August 17, 2026
Ind-Swift Laboratories Ltd. will host its Q1 FY27 earnings call on Monday, August 17, 2026, at 3:00 PM IST. The call will discuss financial results for the quarter ended June 30, 2026. Management will be present.
Read the summary - Medium impact
Ind-Swift Labs: Monitoring Agency Report for Q1FY27 Shows No Deviation in Fund Utilization
Ind-Swift Laboratories Limited's Monitoring Agency Report for Q1FY27 confirms no deviation in fund utilization from its preferential issue. ₹19.82 crore was utilized for expansion. A shortfall of ₹58.99 crore occurred due to lapsed warrants, but the company has sufficient internal funds. Total unutilized funds stand at ₹251.84 crore.
Read the summary - High impact
Ind-Swift Labs Q1 FY27 Profit Jumps 2.04x YoY to ₹24.68 Cr; EBITDA Up 2.85x
Ind-Swift Laboratories reported robust Q1 FY27 results with operating EBITDA up 2.85x YoY to ₹33.32 crore and PAT up 2.04x YoY to ₹24.68 crore. EBITDA margin expanded by 1,258 bps to 17.91%. The company expects FY27 revenue growth exceeding 50% and a medium-term revenue CAGR of 20-25%.
Read the summary - Low impact
Ind-Swift Laboratories: Nil Deviation in Preferential Issue Funds for Q1 FY27
Ind-Swift Laboratories reports no deviation in the utilization of ₹255.61 Crores raised via preferential issue for the quarter ended June 30, 2026. ₹58.99 Crores became non-receivable due to non-exercise of warrants. Total utilization stands at ₹251.84 Crores.
Read the summary - Medium impact
Ind-Swift Laboratories Q1 FY27 PAT at ₹24.44 Cr; Sells Punjab Land for ₹17.50 Cr
Ind-Swift Laboratories reported Q1 FY27 Standalone Net Profit of ₹24.44 Crore, up from ₹8.12 Crore YoY. EBITDA was ₹33.32 Crore. The company also approved the sale of 10 acres of land in Punjab for ₹17.50 Crore, with completion expected in nine months.
Read the summary - Low impact
Ind-Swift Laboratories Approves Amendments to Articles of Association via E-voting
Ind-Swift Laboratories shareholders approved amendments to the Articles of Association via e-voting during an EGM on August 5, 2026. The changes affect director retirement and re-appointment rules, aligning them with the Companies Act, 2013, and SEBI LODR Regulations.
Read the summary - Medium impact
Ind-Swift Laboratories Limited's EGM Approves Preferential Warrants, Director Re-appointment, and AoA Alteration
Ind-Swift Laboratories Limited's EGM on August 5, 2026, passed three special resolutions. These include the issuance of 70 lakh warrants to the promoter group, the re-appointment of Sh. Rajinder Kumar Gupta as an Independent Director for a second five-year term, and the alteration of Article 76 of the Articles of Association. All resolutions passed with a significant majority.
Read the summary - Medium impact
Ind-Swift Laboratories Limited Concludes 1st EGM of FY26-27; Approves Warrant Issuance and Director Re-appointment
Ind-Swift Laboratories Limited held its EGM on August 5, 2026. Shareholders approved the issuance of 70 lakh warrants to promoters and re-appointed Sh. Rajinder Kumar Gupta as an independent director for five years. The company also approved alterations to its Article of Association.
Read the summary - Low impact
Ind-Swift Laboratories Announces Special Window for Physical Share Transfer & Dematerialisation
Ind-Swift Laboratories has opened a Special Window for physical share transfer and dematerialisation, as per SEBI guidelines. Advertisements were published on August 2, 2026. This aims to facilitate the process for shareholders holding physical securities.
Read the summary - Medium impact
Ind-Swift Laboratories Issues Corrigendum to EGM Notice for Preferential Issue
Ind-Swift Laboratories Limited issued a corrigendum to its EGM notice for a preferential issue of 70 lakh warrants. The EGM is on August 5, 2026. Proceeds of ₹137.20 crore will fund facility expansion, R&D, technology upgrades, subsidiary investment, and working capital.
Read the summary - Medium impact
Ind-Swift Laboratories Approves Corrigendum to EGM Notice for Preferential Issue
Ind-Swift Laboratories approved a corrigendum to its EGM notice for a preferential issue of fully convertible warrants. The EGM is scheduled for August 05, 2026. Modifications to the explanatory statement address queries from stock exchanges.
Read the summary - Medium impact
Ind-Swift Laboratories Signs ₹40 Crore MOU for Warehouse Facility
Ind-Swift Laboratories signed an MOU with Him Infratech Private Limited for a new warehouse facility. The project cost is ₹40 Crore and is expected to improve operational efficiencies. The warehouse will have a capacity of 11,000 pallets and is to be completed within 300 days.
Read the summary - Low impact
Ind-Swift Laboratories Announces EGM on August 5, 2026, for Dispatch of Notice
Ind-Swift Laboratories Limited will hold its Extraordinary General Meeting (EGM) on August 5, 2026. The notice for the EGM has been dispatched. Remote e-voting is available from August 2 to August 4, 2026. The cut-off date for voting eligibility is July 29, 2026.
Read the summary - High impact
Ind-Swift Laboratories to hold EGM on Aug 5, 2026, to approve preferential issue of 70 lakh warrants
Ind-Swift Laboratories will hold an EGM on August 5, 2026, to approve issuing 70 lakh warrants to Essix Biosciences Limited for ₹137.20 crore. Sh. Rajinder Kumar Gupta's re-appointment as Independent Director for five years from June 23, 2026, will also be considered. Remote e-voting is available from August 2 to August 4, 2026.
Read the summary - Low impact
Ind-Swift Laboratories Ltd.: SEBI Compliance Certificate for Q1 FY27 Filed
Ind-Swift Laboratories Limited has filed a compliance certificate for the quarter ended June 30, 2026, as per SEBI regulations. The certificate confirms the proper processing of dematerialized securities.
Read the summary - Medium impact
Ind-Swift Laboratories Approves Audited FY26 Financial Results and Reappoints Cost Auditors
Ind-Swift Laboratories Limited's Board approved audited standalone and consolidated financial results for Q4 and FY26 ended March 31, 2026. M/s. V. Kumar & Associates were re-appointed as Cost Auditors for FY27. The company issued 1.80 crore equity shares from warrant conversion and ESOPs.
Read the summary - Medium impact
Ind-Swift Laboratories: Monitoring Agency Report for Q4FY26 Shows No Deviation in Fund Utilization
Ind-Swift Laboratories' Monitoring Agency Report for Q4FY26 confirms no deviation in fund utilization from its ₹314.60 crore preferential issue. Despite a lapse of warrants resulting in a ₹58.99 crore shortfall, the company has sufficient internal funds. Unutilized proceeds stand at ₹23.59 crore.
Read the summary - Medium impact
Ind-Swift Laboratories Shareholders Approve Key Resolutions via Postal Ballot
Ind-Swift Laboratories Limited's shareholders approved four special resolutions through a postal ballot. Key approvals include changes in designation for N.R. Munjal and appointments of Himanshu Jain as MD (Domestic Operations) and Sahil Munjal as MD (Global Operations). Remuneration for Whole-Time Director Rishav Mehta was also approved.
Read the summary - Medium impact
HCP Investments Disposes 7.5% Stake in Ind-Swift Laboratories
HCP Investments has disposed of 6,503,423 equity shares, equivalent to 7.5% of the total paid-up share capital, in Ind-Swift Laboratories Limited. This significant stake sale was disclosed on April 22, 2026, under SEBI takeover regulations.
Read the summary - Low impact
Ind-Swift Laboratories clarifies volume spurt, confirms nil financial impact from arbitration award.
Ind-Swift Laboratories Limited clarified a recent volume spurt, attributing it to market conditions. The company confirmed receipt of an arbitration award on April 7, 2026, rejecting all claims and counterclaims, resulting in nil financial impact. The company adheres to SEBI regulations.
Read the summary - Low impact
Ind-Swift Laboratories Clarifies Share Price Surge, Cites Arbitration Award
Ind-Swift Laboratories Limited clarified a recent surge in its share volume and price, attributing it to market factors and a recent arbitration award. The company announced on April 7, 2026, that an arbitration with PI Industries Limited concluded with the tribunal rejecting all claims and counterclaims, resulting in no financial impact.
Read the summary - Low impact
Ind-Swift Laboratories Limited Wins Arbitration Case Against PI Industries Limited
Ind-Swift Laboratories Limited has concluded arbitration proceedings with PI Industries Limited. The Arbitral Tribunal rejected all claims and counterclaims, resulting in zero financial impact on the company. The final order was passed on April 7, 2026.
Read the summary - Low impact
Ind-Swift Laboratories Publishes Newspaper Clippings for Share Transfer Window
Ind-Swift Laboratories Limited has published newspaper advertisements on April 5, 2026, regarding a Special Window for physical share transfer and dematerialisation. This action is in compliance with a SEBI circular dated January 30, 2026.
Read the summary - Low impact
Ind-Swift Laboratories Files SEBI Compliance Certificate for Q4FY26
Ind-Swift Laboratories Limited filed a compliance certificate for the quarter ended March 31, 2026, as per SEBI regulations. The certificate confirms the dematerialization of securities and cancellation of physical share certificates.
Read the summary - Low impact
Ind-Swift Laboratories: Trading Window Closed from April 1, 2026 for FY26 Audited Results
Ind-Swift Laboratories Limited will close its trading window from April 1, 2026. This is in anticipation of the declaration of audited standalone and consolidated financial results for the quarter and fiscal year ending March 31, 2026. The window will reopen 48 hours after the results are announced.
Read the summary - Low impact
Ind-Swift Laboratories Publishes Newspaper Advertisement for Postal Ballot Notice
Ind-Swift Laboratories Limited published a newspaper advertisement on March 31, 2026. The ad confirmed the dispatch of the Postal Ballot Notice seeking shareholder approval. Details on remote e-voting are also provided. The information is available on the company's website.
Read the summary - Medium impact
Ind-Swift Laboratories to seek shareholder approval for key management changes and remuneration via postal ballot.
Ind-Swift Laboratories is seeking shareholder approval for significant management changes and remuneration through a postal ballot. Key appointments include Sh. Himanshu Jain as MD (Domestic Operations) and Sh. Sahil Munjal as MD (Global Operations). Sh. N.R. Munjal's designation will change to Chairman & Whole-Time Director. Remote e-voting is open from April 1 to April 30, 2026.
Read the summary - Low impact
Ind-Swift Laboratories Appoints Jain & Associates as Internal Auditors for FY27
Ind-Swift Laboratories appointed Jain & Associates as Internal Auditors for FY27. The firm has over 50 years of experience. The appointment is effective from April 1, 2026, to March 31, 2027. Shareholders' approval will be sought via postal ballot for other resolutions.
Read the summary - Medium impact
Ind-Swift Laboratories Achieves EcoVadis Silver Medal, Ranking Top 15% Globally
Ind-Swift Laboratories received the EcoVadis Silver Medal, ranking in the top 15% globally. This recognizes its strong performance in sustainability, ethics, environment, labor, and procurement. The company's Global Business Unit also holds multiple certifications including SMETA, ISO 14001, ISO 45001, ISO 27001, and ISO 37001. These accolades are expected to boost global credibility and market access.
Read the summary - Medium impact
Ind-Swift Laboratories: 65 Lakh Warrants Lapse, ₹19.66 Cr Forfeited
Ind-Swift Laboratories announced the lapse of 65,00,000 convertible warrants from Saral Incorporated VCC Sub Fund 1. The company will forfeit ₹19.66 crore, which was 25% of the issue price for these warrants. The allotment date was August 30, 2024, with an 18-month conversion period.
Read the summary - Medium impact
Essix Biosciences Acquires 51 Lakh Shares, Increases Stake to 37.92%
Essix Biosciences Limited acquired 51,00,000 equity shares of Ind-Swift Laboratories Limited on February 24, 2026, via warrant conversion. This raises their stake to 37.92%. The total promoter group holding is now 43.06%.
Read the summary - Low impact
Ind-Swift Laboratories Schedules Investor Meet with Seven Canyons Funds on March 2, 2026
Ind-Swift Laboratories Limited will hold a virtual one-to-one investor meet with Seven Canyons Funds on March 2, 2026, at 6:30 PM IST. The meeting is facilitated by Stock Pro Advisors. No unpublished price-sensitive information will be shared.
Read the summary - Medium impact
Ind-Swift Laboratories Allots 51 Lakh Equity Shares Via Warrant Conversion
Ind-Swift Laboratories approved the allotment of 51 lakh equity shares via the conversion of fully convertible warrants. The shares were issued to Essix Biosciences Limited at ₹ 121 each. This conversion increases the company's paid-up equity share capital to ₹ 86.71 crore.
Read the summary - Medium impact
Ind-Swift Labs to Invest ₹40 Crore in Samba Facility Upgrade for EU-GMP & PIC/S Compliance
Ind-Swift Laboratories will invest ₹40 crore to upgrade its Samba facility for EU-GMP & PIC/S compliance, aiming to boost exports to regulated markets. The company expects to generate ₹75-80 crore in sales from FY27-28. Q3 FY26 results showed PAT up 22.67% to ₹10.74 crore on revenue of ₹177.06 crore.
Read the summary - High impact
Ind-Swift Labs Investor Presentation: Q3 FY26 Results & Strategic Growth
Ind-Swift Labs reported Q3 FY26 revenue of ₹177.06 Cr, with a 22.6% rise in PAT to ₹10.74 Cr. The company completed a ₹1,650 Cr divestment of its API & CRAMS business, becoming net debt-free. It targets doubling revenue by FY29 and aims for significant growth from CDMO and own-brand segments.
Read the summary - Medium impact
Ind-Swift Laboratories: Monitoring Agency Report for Q3FY26 Shows No Deviation in Preferential Issue Fund Utilization
Ind-Swift Laboratories submitted its Monitoring Agency Report for Q3FY26 regarding its Rs. 314.60 crore preferential issue. CARE Ratings confirmed no deviation in fund utilization. Nil utilization was reported for business expansion and subsidiary investments during the quarter. Rs. 0.46 crore remains unutilized.
Read the summary - Low impact
Ind-Swift Laboratories to Hold Investor Meet on Feb 5, 2026
Ind-Swift Laboratories Limited will hold a virtual one-to-one investor meet with NV Alpha Fund Management on February 5, 2026. No unpublished price sensitive information will be shared during the meeting.
Read the summary - Low impact
Ind-Swift Laboratories Reports NIL Deviation in Preferential Issue Funds for Q3 FY26
Ind-Swift Laboratories confirms no deviation in the utilization of ₹209.41 Crores raised via preferential issue of convertible warrants for the quarter ended December 31, 2025. Funds were allocated for business expansion, subsidiary investment, working capital, and general corporate purposes.
Read the summary - Medium impact
Ind-Swift Laboratories Approves Q3 FY26 Results & Key Management Changes
Ind-Swift Laboratories approved Q3 FY26 results. Key management changes include Navrattan Munjal as Chairman & Whole-Time Director, Himanshu Jain as MD (Domestic), and Sahil Munjal as MD (Global). Remuneration for Rishav Mehta was also approved. Website migration to www.indswiftgroup.com is expected by March 31, 2026.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio